| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/09/2008 | EP1874737A1 Substituted 2-amin0alkylthi0-benzimidaz0les and use thereof for reducing blood sugar levels |
| 01/09/2008 | EP1874736A2 Fused heterocyclic compounds |
| 01/09/2008 | EP1874735A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 01/09/2008 | EP1874734A1 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators |
| 01/09/2008 | EP1874733A1 Substituted cyclic urea derivatives and the use thereof as vanilloid receptor 1 modulators |
| 01/09/2008 | EP1874732A1 Pyrazole derivatives as progesterone receptor antagonists |
| 01/09/2008 | EP1874731A2 Quinobenzoxazine analogs and methods of using thereof |
| 01/09/2008 | EP1874730A1 Substituted butyrophenone derivatives |
| 01/09/2008 | EP1874727A1 New muscarinic receptor antagonists |
| 01/09/2008 | EP1874726A2 Organic compounds |
| 01/09/2008 | EP1874724A2 Phenyl ethyne compounds |
| 01/09/2008 | EP1874723A2 New nitrogenated trans-stilbene analogs, method for the obtention and medical applications thereof |
| 01/09/2008 | EP1874721A2 Glycine transport inhibitors |
| 01/09/2008 | EP1874410A1 Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient |
| 01/09/2008 | EP1874354A1 Nutrient composition comprising green tea polyphenols for treating osteosarcoma |
| 01/09/2008 | EP1874349A2 Use of cd25 antibodies in immunotherapy |
| 01/09/2008 | EP1874342A2 Compositions and methods for cancer immunotherapy |
| 01/09/2008 | EP1874340A2 Elastin protective polyphenolics and methods of using the same |
| 01/09/2008 | EP1874336A2 Method of improving learning and memory in mammals |
| 01/09/2008 | EP1874334A2 Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease |
| 01/09/2008 | EP1874325A2 Methods for treating infectious disease exacerbated asthma |
| 01/09/2008 | EP1874324A1 Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes |
| 01/09/2008 | EP1874323A1 Tamponade compositions and methods for retinal repair |
| 01/09/2008 | EP1874322A1 Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci |
| 01/09/2008 | EP1874321A2 Compositions for the treatment of neoplasms |
| 01/09/2008 | EP1874320A1 Composition of film-forming solution type, comprising vitamin d or a derivative thereof and a corticosteroid, and use thereof in dermatology |
| 01/09/2008 | EP1874319A2 Formulations of quaternary ammonium neuromuscular blocking agents |
| 01/09/2008 | EP1874318A2 N-alkyl-azacycloalkyl nmda/nr2b antagonists |
| 01/09/2008 | EP1874317A2 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity |
| 01/09/2008 | EP1874316A1 Use of pde-5 inhibitors for endothelial repair of tissues impaired by trauma or disease |
| 01/09/2008 | EP1874315A2 Compositions of novel opioid compounds and method of use thereof |
| 01/09/2008 | EP1874314A2 Pellet-type controlled-release preparation containing cinnarizine and dimenhydrinate for combating vertigo |
| 01/09/2008 | EP1874313A1 Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist |
| 01/09/2008 | EP1874312A2 Methods and means for the treatment of hpv induced intraepithelial neoplasias |
| 01/09/2008 | EP1874311A2 A method for preventing, delaying or reverting abnormal amyloid deposition |
| 01/09/2008 | EP1874310A2 Opioid receptor agonist compounds and their use in treatment of pain |
| 01/09/2008 | EP1874309A1 Roflumilast for the treatment of pulmonary hypertension |
| 01/09/2008 | EP1874308A1 Roflumilast for the treatment of diabetes mellitus |
| 01/09/2008 | EP1874307A2 Use of a sulfonamide compound for improving the pharmacokinetics of a drug |
| 01/09/2008 | EP1874306A1 Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| 01/09/2008 | EP1874305A2 Substituted oxazole derivatives and their use as tyrosine kinase inhibitors |
| 01/09/2008 | EP1874304A2 Benzotriazole derivatives as cannabinoid receptor antagonists |
| 01/09/2008 | EP1874303A1 Pyrazole compounds as prostaglandin receptors ligands |
| 01/09/2008 | EP1874302A1 Angiotensin ii receptor antagonists |
| 01/09/2008 | EP1874301A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 01/09/2008 | EP1874300A2 Method for treating apathy syndrome |
| 01/09/2008 | EP1874299A2 Vla-4 antagonists |
| 01/09/2008 | EP1874298A2 Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3,1,0]hexanes |
| 01/09/2008 | EP1874297A1 Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor |
| 01/09/2008 | EP1874296A2 Method of treating multiple myeloma using 17-aag of 17-ag of a prodrug of either |
| 01/09/2008 | EP1874295A1 Benzothiophene derivatives |
| 01/09/2008 | EP1874294A1 Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions |
| 01/09/2008 | EP1874293A1 Association between ferroquine and an artemisinine derivative for treating malaria |
| 01/09/2008 | EP1874292A2 Methods for modulating bladder function |
| 01/09/2008 | EP1874291A2 Novel use of zinc gluconate for treating hydradenitis suppurativa |
| 01/09/2008 | EP1874290A1 A process for the preparation of an oxaliplatin preparation |
| 01/09/2008 | EP1874289A2 Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
| 01/09/2008 | EP1874288A1 Acetyl l-carnitine for preventing painful peripheral diabetic neuropathy |
| 01/09/2008 | EP1874287A2 Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
| 01/09/2008 | EP1874286A2 Methods and compositions for the treatment of anxiety disorders |
| 01/09/2008 | EP1874285A2 Complementary compositions to reduce blood glucose levels and treat diabetes |
| 01/09/2008 | EP1874284A2 Eutectic blends containing a water soluble vitamin derivative |
| 01/09/2008 | EP1874283A2 Use of novel compounds for ibd treatment |
| 01/09/2008 | EP1874282A2 Methods and compositions for treatment of cns disorders |
| 01/09/2008 | EP1874281A2 Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue |
| 01/09/2008 | EP1874280A2 Topical treatment with ngf and dha in damaged corneas |
| 01/09/2008 | EP1874279A2 Water-soluble films comprising nicotine |
| 01/09/2008 | EP1874278A2 Compositions containing micronized tanaproget |
| 01/09/2008 | EP1874277A1 Sustained release l-arginine formulations and methods of manufacture and use |
| 01/09/2008 | EP1874271A1 Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer |
| 01/09/2008 | EP1874270A2 Pharmaceutical aerosol composition |
| 01/09/2008 | EP1874269A2 Combination of tramadol and substances that comprise gabapentin |
| 01/09/2008 | EP1874268A1 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
| 01/09/2008 | EP1874267A1 Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles |
| 01/09/2008 | EP1874223A2 Elastin stabilization of connective tissue |
| 01/09/2008 | EP1874138A2 Nutrition with lipids and non-digestible saccharides |
| 01/09/2008 | EP1874136A2 Nutritional supplement for a category of hiv patients |
| 01/09/2008 | EP1874118A2 Materials and methods for enhanced degradation of mutant proteins associated with human disease |
| 01/09/2008 | EP1874117A1 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
| 01/09/2008 | EP1874116A1 Compounds, pharmaceutical compositions and methods for inhibiting hiv infectivity |
| 01/09/2008 | EP1765842B1 D-xylopyranosyl-substituted phenyls, medicaments containing said compounds, the use thereof, and methods for producing the same |
| 01/09/2008 | EP1763533B1 Specific antagonist for both e- and p-selectins |
| 01/09/2008 | EP1761541B1 Pyrrazolo-pyrimidine derivatives |
| 01/09/2008 | EP1751100B1 Anti-tubulin acting arylpyrrol, arylfulran and arylthiopene derivatives, method for the preparation and use thereof as an antimitotic |
| 01/09/2008 | EP1732887B1 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine (ne) and the serotonine (5-ht) activity and the monoamine reuptake for the treatment of vasomotor symptoms (vms) |
| 01/09/2008 | EP1711473B1 Substituted n-cyclohexylimidazolinones having an mch-modulatory effect |
| 01/09/2008 | EP1685142B1 Phosphinic acid derivatives, beta-secretase inhibitors for the treatment of alzheimer's disease |
| 01/09/2008 | EP1684706A4 Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter |
| 01/09/2008 | EP1682146B1 Antimycotic nail polish formulations comprising substituted 2-aminothiazoles as an active substance |
| 01/09/2008 | EP1653950B1 Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases |
| 01/09/2008 | EP1638934B1 3-aminopyrrolidines as inhibitors of monoamine uptake |
| 01/09/2008 | EP1620409B1 Quinoxalin-3-one derivatives as orexin receptor antagonists |
| 01/09/2008 | EP1610760A4 Topical l-carnitine compositions |
| 01/09/2008 | EP1608647B1 5-phenylthiazole derivatives and their use as p13 kinase inhibitors |
| 01/09/2008 | EP1605927B1 Anti-microbially active diamine-based guanine derivatives |
| 01/09/2008 | EP1583756B9 Thiophene carboxamides as inhibitors of the enzyme ikk-2 |
| 01/09/2008 | EP1556378B1 Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity |
| 01/09/2008 | EP1527068B1 Novel arylimidazole derivatives, their use as no-syntase inhibitors and as modulators of sodium channels |
| 01/09/2008 | EP1527048B1 N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy |
| 01/09/2008 | EP1501828B1 Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders |